LBP-24-Safety, tolerability and efficacy of volixibat, an apical sodium-dependent bile acid transporter inhibitor, in adults with nonalcoholic steatohepatitis: 24-week interim analysis results from a phase 2 study

Authors :: Aasim Sheikh
Harry Sarles
Philip N. Newsome
Robert Herring
Parvez S. Mantry
Melissa Palmer
Guruprasad P. Aithal
Zeid Kayali
Bradley Freilich
Tarek Hassanein
Yi Chen
Muhammad Y. Sheikh
Source :: Journal of Hepatology. 70:e152-e153
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Nonalcoholic steatohepatitis
medicine.medical_specialty
Hepatology
business.industry
Internal medicine
Apical sodium-dependent bile acid transporter
medicine
Phases of clinical research
Safety tolerability
Interim analysis
business
Gastroenterology

Full Text Access

Tools